JP-2022512538-A5 -

Dates

Publication Date

20221205

Application Date

20191126

Description

No reference, including any non-patent or patent documents cited herein, constitutes prior art. Unless otherwise stated, any reference to any document herein is understood not to constitute an admission that any of these documents form part of common technical knowledge in the art in the United States or any other country. Any consideration of the above references represents the claims of their authors, and the applicant reserves the right to object to the accuracy and appropriateness of any of the documents cited herein. All references cited herein are provided solely for informational purposes unless expressly indicated otherwise. In the event of any inconsistency between any definition and/or any statement found in a cited document, this disclosure shall prevail. The present invention provides, for example, the following items. (Item 1) A population of T cells containing an engineered T cell receptor (TCR), wherein the engineered TCR activates T cells in response to the latent membrane protein 2 (LMP2) antigen. (Item 2) The manipulated TCR is a population of T cells as described in item 1, comprising the amino acid sequence of sequence number 03. (Item 3) The manipulated TCR is a population of T cells as described in item 1, comprising the amino acid sequence of sequence number 09. (Item 4) The LMP2 antigen is a population of T cells as described in any of items 1 to 3, comprising the sequence SSCSSCPLSK (Sequence ID 01). (Item 5) The T cell population is a T cell population according to any one of items 1 to 4, comprising a therapeutically effective amount of cells for treating cancer containing LMP2 in the subject. (Item 6) The subject is a population of T cells expressing human leukocyte antigen subtype A11 (HLA-A11), as described in any of items 1 to 5. (Item 7) A population of T cells according to any one of items 1 to 6, wherein at least a portion of the population of T cells produces or is capable of producing one or more cytokines. (Item 8) The T cell population described in item 7, wherein one or more of the aforementioned cytokines are selected from the group consisting of IL-2, IFN-γ, TNF-α, granzyme A, granzyme B, and GM-CSF. (Item 9) The aforementioned cancers are a population of T cells described in any of items 6 to 8, selected from the group consisting of nasopharyngeal carcinoma (NPC), lymphoma, gastric cancer, lung cancer, melanoma, breast cancer, prostate cancer, colon cancer, renal cell carcinoma, ovarian cancer, neuroblastoma, rhabdomyosarcoma, and leukemia. (Item 10) The aforementioned cancer is an EBV-related cancer, a population of T cells as described in item 9. (Item 11) The aforementioned cancer is nasopharyngeal carcinoma (NPC), a population of T cells as described in item 9. (Item 12) The aforementioned cancer is lymphoma, a population of T cells as described in item 9. (Item 13) The aforementioned cancer is gastric cancer, a population of T cells as described in item 9. (Item 14) A pharmaceutical composition comprising a population of T cells described in any of items 1 to 13, and a pharmaceutically acceptable carrier. (Item 15) The pharmaceutically acceptable carrier is a pharmaceutically acceptable amount of LMP2 in the pharmaceutically acceptable composition according to item 14, which supports cell maintenance for cancer treatment. (Item 16) A pharmaceutical composition according to item 14 or 15, further comprising at least one therapeutic agent. (Item 17) A method for treating a subject suffering from cancer containing LMP2, the method comprising administering to the subject a therapeutically effective amount of a population of T cells described in any of items 1 to 13 or a pharmaceutical composition described in any of items 14 to 16, wherein the administration induces an antitumor response against the cancer. (Item 18) The method according to item 17, wherein the cancer is selected from the group consisting of nasopharyngeal carcinoma (NPC), lymphoma, gastric cancer, lung cancer, melanoma, breast cancer, prostate cancer, colon cancer, renal cell carcinoma, ovarian cancer, neuroblastoma, rhabdomyosarcoma, and leukemia. (Item 19) The method described in item 18, wherein the cancer is EBV-related cancer. (Item 20) The cancer is nasopharyngeal carcinoma (NPC), as described in item 18. (Item 21) The cancer is lymphoma, as described in item 18. (Item 22) The cancer is gastric cancer, according to the method described in item 18. (Item 23) The antitumor response, according to any one of items 17 to 22, results in a reduction of tumor volume of at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100%. (Item 24) An isolated nucleic acid molecule containing a polynucleotide encoding an engineered TCR with the amino acid sequence of SEQ ID NO: 03. (Item 25) The polynucleotide is an isolated nucleic acid as described in item 24, comprising the nucleic acid sequence of sequence number 08. (I